DISCOUNT OPTIONSSCHEIN - AMGEN | Real-time Bid/Ask 09:20:30 2024-06-28 am EDT | ||
| 4.77 EUR / 5.01 EUR | +5.62% |
|
| Current month | +26.16% | ||
| 1 month | +19.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 4.81 | +3.89% |
| 24-06-27 | 4.63 | -7.03% |
| 24-06-26 | 4.98 | -4.96% |
| 24-06-25 | 5.24 | +5.43% |
| 24-06-24 | 4.97 | +8.52% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:52 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME6QK2 |
| ISIN | DE000ME6QK20 |
| Date issued | 2024-01-10 |
| Strike | 380 $ |
| Maturity | 2024-12-20 (175 Days) |
| Parity | 1 : 1 |
| Emission price | 3.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.36 € |
|---|---|
| Lowest since issue | 1.77 € |
| Spread | 0.23 € |
| Spread % | 4.59% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
313.7
USD
Average target price
316.4
USD
Spread / Average Target
+0.88%
- Stock Market
- Certificates
- Certificat
